Drug Profile
Tetradecanoylphorbol acetate - Biosuccess Biotech/Rich Pharmaceuticals
Alternative Names: PD-616; Phorbol 12-myristate 13-acetate; Phorbol myristate acetate; PMA; RP 323; TPALatest Information Update: 07 Jan 2022
Price :
$50
*
At a glance
- Originator Rutgers; Zhengzhou University
- Developer Biosuccess Biotech; Rich Pharmaceuticals; Rutgers
- Class Antineoplastics; Antiretrovirals; Phorbol esters; Small molecules
- Mechanism of Action Apoptosis stimulants; Mitogen-activated protein kinase modulators; Protein kinase C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia
- Phase I/II Myelodysplastic syndromes
- No development reported HIV infections; Hodgkin's disease; Stroke
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for clinical-Phase-Unknown development in Acute-myeloid-leukaemia in China (IV, Infusion)
- 03 Mar 2021 No development reported - Phase-I/II for Hodgkin's disease in USA (IV)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (IV, Infusion)